Negative_JJ
transcriptional_JJ
regulation_NN
of_IN
human_JJ
interleukin_NN
2_CD
-LRB-_-LRB-
IL-2_NN
-RRB-_-RRB-
gene_NN
by_IN
glucocorticoids_NNS
through_IN
interference_NN
with_IN
nuclear_JJ
transcription_NN
factors_NNS
AP-1_NN
and_CC
NF-AT_NN
._.

IL-2_NN
gene_NN
transcription_NN
is_VBZ
affected_VBN
by_IN
several_JJ
nuclear_JJ
proteins_NNS
._.

We_PRP
asked_VBD
whether_IN
dexamethasone_NN
-LRB-_-LRB-
Dex_NN
-RRB-_-RRB-
and_CC
cyclosporin_NN
A_NN
-LRB-_-LRB-
CsA_NN
-RRB-_-RRB-
inhibit_VBP
IL-2_NN
gene_NN
transcription_NN
by_IN
interfering_VBG
with_IN
the_DT
activity_NN
of_IN
nuclear_JJ
proteins_NNS
that_WDT
bind_VBP
to_TO
the_DT
IL-2_NN
promoter_NN
._.

Nuclear_JJ
extracts_NNS
from_IN
primary_JJ
human_JJ
T_NN
lymphocytes_NNS
were_VBD
analyzed_VBN
by_IN
electrophoretic_JJ
DNA_NN
mobility_NN
shift_NN
assays_NNS
._.

Both_CC
Dex_NN
and_CC
CsA_NN
inhibited_VBD
the_DT
binding_NN
of_IN
transcription_NN
factors_NNS
AP-1_NN
and_CC
NF-AT_NN
,_,
but_CC
not_RB
of_IN
NF-kB_NN
and_CC
OCT-1_NN
\/_:
OAF_NN
,_,
to_TO
their_PRP$
corresponding_JJ
sites_NNS
on_IN
the_DT
IL-2_NN
gene_NN
promoter_NN
._.

To_TO
correlate_VB
changes_NNS
in_IN
nuclear_JJ
factor_NN
binding_NN
in_FW
vitro_FW
with_IN
transcriptional_JJ
activity_NN
in_FW
vivo_FW
and_CC
define_VB
the_DT
structural_JJ
requirements_NNS
for_IN
IL-2_NN
promoter_NN
repression_NN
,_,
we_PRP
used_VBD
transient_JJ
DNA_NN
transfections_NNS
._.

Jurkat_NN
cells_NNS
were_VBD
transfected_VBN
with_IN
plasmids_NNS
containing_VBG
either_CC
the_DT
intact_JJ
IL-2_NN
promoter_NN
or_CC
its_PRP$
AP-1_NN
,_,
NF-AT_NN
,_,
and_CC
NF-kB_NN
motifs_NNS
._.

Dex_NN
inhibited_VBD
the_DT
IL-2_NN
promoter_NN
and_CC
the_DT
AP-1_NN
,_,
but_CC
not_RB
the_DT
NF-AT_NN
and_CC
NF-kB_NN
plasmids_NNS
._.

In_IN
contrast_NN
,_,
CsA_NN
inhibited_VBD
the_DT
IL-2_NN
promoter_NN
and_CC
the_DT
NF-AT_NN
,_,
but_CC
not_RB
the_DT
AP-1_NN
and_CC
NF-kB_NN
plasmids_NNS
._.

These_DT
results_NNS
suggest_VBP
that_IN
in_IN
human_JJ
T_NN
lymphocytes_NNS
both_CC
Dex_NN
and_CC
CsA_NN
inhibited_VBD
IL-2_NN
gene_NN
transcription_NN
through_IN
interference_NN
with_IN
transcription_NN
factors_NNS
AP-1_NN
and_CC
NF-AT_NN
._.

We_PRP
propose_VBP
that_IN
,_,
while_IN
maximum_NN
inhibition_NN
may_MD
involve_VB
interaction_NN
with_IN
both_DT
transcription_NN
factors_NNS
,_,
AP-1_NN
is_VBZ
the_DT
primary_JJ
target_NN
of_IN
Dex_NN

